-
公开(公告)号：US20160347845A1
公开(公告)日：2016-12-01
申请号：US15234581
申请日：2016-08-11
Applicant: Acceleron Pharma Inc. , Dyax Corp.
Inventor： Ravindra Kumar , Asya Grinberg , Monique Davies , Diana Martik , Janja Cosic , Rachel Kent , David Buckler
IPC: C07K16/28
CPC classification number: C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
Abstract translation: 本公开尤其提供了中和抗体及其与ActRIIB结合并用于其的部分。
-
公开(公告)号：US20220098309A1
公开(公告)日：2022-03-31
申请号：US17245526
申请日：2021-04-30
Applicant: Acceleron Pharma Inc. , Dyax Corp.
Inventor： Ravindra Kumar , Asya Grinberg , Monique Davies , Diana Martik , Janja Cosic , Rachel Kent , David Buckler
Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
-
公开(公告)号：US20190023797A1
公开(公告)日：2019-01-24
申请号：US16054446
申请日：2018-08-03
Applicant: Acceleron Pharma Inc. , Dyax Corp.
Inventor： Ravindra Kumar , Asya Grinberg , Monique Davies , Diana Martik , Janja Cosic , Rachel Kent , David Buckler
Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
-
公开(公告)号：US20180051088A1
公开(公告)日：2018-02-22
申请号：US15477204
申请日：2017-04-03
Applicant: Acceleron Pharma Inc. , Dyax Corp.
Inventor： Ravindra Kumar , Asya Grinberg , Monique Davies , Diana Martik , Janja Cosic , Rachel Kent , David Buckler
IPC: C07K16/28
CPC classification number: C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
-
公开(公告)号：US09624301B2
公开(公告)日：2017-04-18
申请号：US15234581
申请日：2016-08-11
Applicant: Acceleron Pharma Inc. , Dyax Corp.
Inventor： Ravindra Kumar , Asya Grinberg , Monique Davies , Diana Martik , Janja Cosic , Rachel Kent , David Buckler
IPC: C07K16/28
CPC classification number: C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
-
Patent Agency Ranking
公开(公告)号：US20250066488A1
公开(公告)日：2025-02-27
申请号：US18947795
申请日：2024-11-14
Applicant: Acceleron Pharma Inc. , Dyax Corp.
Inventor： Ravindra Kumar , Asya Grinberg , Monique Davies , Diana Martik , Janja Cosic , Rachel Kent , David Buckler
Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
-
公开(公告)号：US20250109179A1
公开(公告)日：2025-04-03
申请号：US18811531
申请日：2024-08-21
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Dianne S. Sako , Roselyne Castonguay , Tzu-Hsing Kuo
IPC: C07K14/705 , A61K38/00 , C07K14/71 , C07K16/22
Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIA:TβRII heteromultimers comprising an ActRIIA polypeptide and a TβRII polypeptide). The disclosure further provides that such multispecific binders (e.g., ActRIIA:TβRII heteromultimer) may be used to treat various disorders or conditions.
-
公开(公告)号：US12042524B2
公开(公告)日：2024-07-23
申请号：US17231981
申请日：2021-04-15
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Jonathan Belk , Asya Grinberg , Dianne Sako , Roselyne Castonguay
CPC classification number: A61K38/02 , A61K38/16 , C07K14/001 , C07K14/47 , C07K16/2863 , A61K38/00 , C07K5/00 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated musle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
公开(公告)号：US12024563B2
公开(公告)日：2024-07-02
申请号：US17505124
申请日：2021-10-19
Applicant: Acceleron Pharma Inc.
Inventor： John Knopf , Ravindra Kumar , Asya Grinberg , Robert Scott Pearsall , Dianne S. Sako , Roselyne Castonguay , Gang Li , Yossi Dagon
CPC classification number: C07K16/2863 , A61K38/1709 , A61K38/177 , C07K14/71 , C12N9/1205 , C07K2317/76 , C07K2319/00 , C07K2319/10 , C07K2319/20 , C07K2319/30 , C07K2319/35 , C07K2319/70 , C07K2319/74
Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.
-
公开(公告)号：US11981738B2
公开(公告)日：2024-05-14
申请号：US16757959
申请日：2018-10-25
Applicant: Acceleron Pharma Inc. , Adimab, LLC
Inventor： Ravindra Kumar , Roselyne Castonguay , Dianne Sako , Jonathan Belk , Nathan J. Sharkey
IPC: A61K39/395 , A61P3/06 , C07K16/28 , A61K39/00
CPC classification number: C07K16/2863 , A61P3/06 , A61K2039/505 , C07K2317/34 , C07K2317/92
Abstract: The disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, obesity, type 2 diabetes, and their associated conditions, metabolic disorders, and other diseases or conditions that can be treated by targeting ALK7.
-
-
-
-
-
-
-
-
-
Search Results
248
records
(took 0.025 seconds)
